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Abstract
Background: Desmoplastic Small Round Cell Tumor (DSRCT) is a highly aggressive malignancy that affects mainly
adolescents and young adults. A defining characteristic of DSRCT is a specific chromosomal translocation, t(11;22)(p13;q12),
that fuses EWS with WT1, leading to a production of two isoforms of chimeric transcription factor, EWS/WT1(2KTS) and
EWS/WT1(+KTS). The chimeric proteins are thought to play critical roles in various stages of oncogenesis through aberrant
transcription of different genes, but only a few of these genes have been identified.
Methodology/Principal Findings: We report the identification of a new target of EWS/WT1, ENT4 (equilibrative nucleoside
transporter 4) which encodes a pH-dependent adenosine transporter. ENT4 is transcriptionally activated by both isoforms of
EWS/WT1 as evidenced by promoter-reporter and chromatin immunoprecipitation (ChIP) analyses. Furthermore, ENT4 is
highly and specifically expressed in primary tumors of DSRCT as well as in a DSRCT cell line, JN-DSRCT-1. Treatment of JN-
DSRCT-1 cells with adenosine analogs, such as 2-chloro-29-deoxyadenosine (2-CdA), resulted in an increased cytotoxic
response in dose- and pH-dependent manner.
Conclusions/Significance: Our detailed analyses of a novel target of EWS/WT1 in DSRCT reveal an insight into the
oncogenic mechanism of EWS-fusion chromosomal translocation gene products and provide a new marker for DSRCT.
Furthermore, identification of ENT4 as a highly expressed transcript in DSRCT may represent an attractive pathway for
targeting chemotherapeutic drugs into DSRCT.
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Introduction
Desmoplastic small round cell tumor (DSRCT) is a rare and
poorly understood neoplasm with extremely poor prognosis.
Tumors are frequently found in the serosal surface of abdomen
and pelvis, although tumors arising from other sites have been
described [1–3]. It is characterized histologically by solid nests of
small neoplastic cells surrounded by dense stromal components
consisting of fibroblasts and hyperplastic blood vessels (reviewed in
[4]). The tumor cells are positive for epithelial, mesenchymal, and
neural markers, thereby confounding the tumor cell origin.
Genetic studies revealed that all cases of DSRCT harbor the
t(11;22)(p13;q12) translocation, leading to a fusion of the N-
terminal domain (NTD) of Ewing’s sarcoma gene (EWS) to the C-
terminal DNA binding domain of Wilms tumor suppressor gene,
WT1 [5,6]. This unique chromosomal translocation provides the
definitive molecular diagnosis of DSRCT and creates an aberrant
transcription factor, EWS/WT1, which underlies the oncogenesis
of DSRCT.
The EWS gene was first cloned from the Ewing’s sarcoma
chromosomal breakpoint, where the translocation generates a
fusion between EWS and an ETS-family transcription factor gene,
FLI-1 [7]. EWS encodes a putative RNA binding protein, which
together with TLS/FUS and TAFII68/TAF15 form the TET
family of proteins with presumptive roles in transcription and
splicing [8]. The NTD of EWS mediates potent transcriptional
activation when fused to a heterologous DNA binding domain [9],
while its C-terminal domain, which is lost in the translocation gene
product, is involved in RNA recognition [10]. Recently, EWS was
shown to be essential for meiosis, B-cell development and cellular
senescence [11], as well as in mitosis [12].
The Wilms tumor suppressor gene WT1 encodes a Kruppel-like
transcription factor which is mutated in a subset of Wilms tumor, a
childhood kidney cancer [13]. WT1 encodes four Cys2His2 zinc-
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binding and the NTD containing both transcriptional activation
and repression domains [14,15]. WT1 is subjected to two
alternative splicing events, one of which involves the inclusion or
exclusion of three amino acids, lysine, threonine and serine (KTS),
between the zinc-fingers 3 and 4 [16]. The KTS insertion leads to
a markedly decreased DNA binding affinity of WT1 [17]. In
nearly all cases of DSRCT, only the last 3 exons of WT1 encoding
the last three zinc fingers are fused to the NTD of EWS, and the
alternative KTS splicing of WT1 is preserved [6]. As a result,
EWS/WT1 produces two isoforms: EWS/WT1(2KTS) and
EWS/WT1(+KTS) that differs in the DNA binding affinity and
specificity [18]. It was subsequently shown that only the EWS/
WT1(2KTS) isoform, but not the EWS/WT1(+KTS), possesses
the transforming activity in NIH3T3 cell-based assays [19].
Therefore, most efforts have focused on the identification of
transcriptional targets of the EWS/WT1(2KTS) isoform.
To date, a small number of direct transcriptional targets of
EWS/WT1(2KTS) have been identified (reviewed in [4]), which
include PDGF-A (platelet-derived growth factor A) [20], IGFR1
(insulin-like growth-factor receptor 1) [21], IL2RB (interleukin 2
receptor beta) [22], BAIAP3 (BAI1-associated protein 3) [23], a
potential regulator of growth-factor release, and TALLA-1 (T-cell
acute lymphoblastic leukemia-associated antigen 1) [24], a gene
encoding a tetraspanin-family protein. In contrast, there is only a
single target gene identified for EWS/WT1(+KTS), which is
LRRC15 (leucine-rich repeat containing 15) [25], a gene
implicated in cell invasion. The native WT1(6KTS) isoforms do
not regulate any of these transcripts, indicating that the loss of zinc
finger 1 and/or the presence of EWS transactivation domain
(NTD) may confer differential target gene specificity to EWS/
WT1. Another interesting observation is that all of the identified
target genes are regulated specifically by either the EWS/
WT1(2KTS) or the (+KTS), but not both, clearly demonstrating
the differential target gene specificity of the two isoforms.
ENT4 (equilibrative nucleoside transporter 4) is a member of the
equilibrative nucleoside transporter (ENT) family (SLC29) and has
recently been shown to be a pH-dependent adenosine transporter
[26,27]. Interestingly, ENT4 also accepts a number of biogenic
amines as substrates and was alternatively named plasma
membrane monoamine transporter (PMAT) [28]. In this study,
we demonstrate that ENT4 is transcriptionally activated by both
isoforms of EWS/WT1 and is highly expressed in DSRCT,
implicating ENT4 as a potential therapeutic target.
Results
Identification of ENT4 as a target gene of EWS/
WT1(2KTS) and EWS/WT1(+KTS)
To identify the direct target genes of EWS/WT1(2KTS), we
have previously performed expression profiling analysis with an
inducible cell line expressing EWS/WT1(2KTS) [23]. This
approach identified a number of EWS/WT1(2KTS) target genes
which include several known genes and ESTs [4,22,23]. In the
present study, we further characterized one of the EST transcripts
(GenBank accession # R13346) which was induced by EWS/
WT1(2KTS) expression with variable magnitudes in duplicate
microarray experiments (21.0- and 3.1-fold induction). Sequence
analysis revealed that the EST belongs to a recently identified
novel monoamine transporter, PMAT [28], and independently
identified as a new member of equilibrative nucleoside transporter,
ENT4, with high-affinity for adenosine [29]. To validate this
finding, we generated an independent tetracycline (Tet)-repressible
EWS/WT1(2KTS) expressing cell line, UF5. A quantitative
measurement of ENT4 transcripts following the induction of
EWS/WT1(2KTS) for 12 hrs in UF5 cells demonstrated a 4-fold
increase in endogenous ENT4 expression (Fig. 1B). The presence
or absence of Tet in the control UV9 cells did not affect the level
of ENT4 expression. To determine whether the induction of ENT4
was specific to the EWS/WT1(2KTS) isoform, we examined
ENT4 expression in UED5 cells expressing EWS/WT1(+KTS).
Surprisingly, we observed a robust 7-fold induction of ENT4
following the expression of EWS/WT1(+KTS), which is higher
than the 4-fold induction observed with EWS/WT1(2KTS)
expression (Fig. 1B). The difference in the magnitude of ENT4
induction was not due to the difference in the expression levels of
the two EWS/WT1 isoforms, since the 2KTS was expressed at a
higher level in UF5 cells than the +KTS in UED5 cells as
demonstrated by SYBR Green quantitative RT-PCR (qRT-PCR)
(Supplement Fig. S1). In addition, an inducible expression of
native WT1, either the 2KTS or +KTS, did not alter the level of
endogenous ENT4 expression (data not shown), demonstrating
that ENT4 is specifically activated by EWS/WT1. Thus, ENT4
represents the first target gene which is transcriptionally activated
by both isoforms of EWS/WT1.
Tumor-specific expression of ENT4 in DSRCT
To establish ENT4 as a physiological target of EWS/WT1, we
next examined the expression of ENT4 in primary DSRCT
samples. Total RNAs from four DSRCT and three Ewing’s
sarcoma tumor specimens as well as normal human tissues were
isolated and analyzed for ENT4 expression by qRT-PCR. All four
DSRCT specimens showed higher expression of ENT4 than any of
the Ewing’s sarcoma samples (Fig. 1C, left panel) or the two tissues
(brain and heart) where ENT4 is reported to be highly expressed
[26] (Fig. 1C, right panel). In fact, compared to the Ewing’s
sarcoma case (#6052) with the highest ENT4 expression, DSRCT
samples expressed at least 2- to 20-fold higher level of ENT4
transcripts. Importantly, RNA in-situ analysis with two cases of
DSRCT clearly revealed a tumor-specific ENT4 expression with
little or no expression in the surrounding stromal tissues (Fig. 1D).
These results establish that ENT4 is a physiological target of EWS/
WT1 and is highly expressed by the tumor cells of DSRCT.
ENT4 promoter is transactivated by both isoforms
of EWS/WT1
We next wished to determine whether EWS/WT1(6KTS)
isoforms can directly and independently transactivate the
promoter of ENT4. We amplified approximately 2-kb proximal
promoter region of ENT4, including the first exon containing the
59 UTR, (Fig. 2A) and inserted it into a promoterless pGL3-Basic
luciferase plasmid (P1). Co-transfection of either EWS/
WT1(2KTS) or EWS/WT1(+KTS) with the 2-kb promoter
construct P1 resulted in a marked transcriptional activation of the
ENT4 promoter by both isoforms (Fig. 2C). Consistent with our
previous results (Fig. 1B), EWS/WT1(+KTS) expression led to a
higher activation of the ENT4 promoter (10-fold) than EWS/
WT1(2KTS) (6-fold). These results suggest that two isoforms can
directly and independently transactivate ENT4 expression.
Identification of the 2KTS and +KTS specific responsive
elements in ENT4 promoter
EWS/WT1(2KTS) has been shown to bind to either a GC-rich
sequence (59-GXGGXGGXG-39) [18] or a E-WRE sequence (59-
(G/C)(C/G)(G/C)TGGGGG-39) [22]. On the other hand, EWS/
WT1(+KTS) binds to a novel recognition sequence termed,
E(KTS)RE, which has been defined as (59-GGAGG(A/G)-39)
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revealed three potential EWS/WT1(2KTS) responsive elements
(GC-rich) located downstream of the transcriptional start site and
a 760-bp stretch of GA-repeats, which contains more than 50
potential +KTS binding sites, E(KTS)RE motif, located upstream
of the transcriptional start site (Fig. 2A). To test whether these
sequences can function as the cis-regulatory elements, we
generated various promoter deletion constructs (Fig. 2B). A
deletion of 1700-bp region (21450 to +270) upstream of the
GC-rich sequences (promoter P2), which includes the GA-repeat
sequences containing more than 50 potential E(KTS)RE elements,
resulted in a complete loss of EWS/WT1(+KTS)-mediated
transactivation (Fig. 2C). A smaller deletion encompassing mostly
the GA-repeat sequences (promoter P3) also completely abrogated
the +KTS-mediated transactivation of the ENT4 promoter,
demonstrating that the multiple E(KTS)RE sites in the GA-repeat
sequences likely function as the EWS/WT1(+KTS) response
element. In contrast, the P2 promoter (330-bp) containing mostly
the GC-rich sequences was highly activated (21-fold) by EWS/
WT1(2KTS), indicating that the GC-rich sequences likely
mediate the transactivation by the 2KTS isoform. EWS/
WT1(2KTS) activated the P3 promoter to a similar level (5-fold)
as the 2-kb P1 promoter (6-fold), indicating that the removal of
negative elements in the 59 upstream region (21450 to 2915) of
the human ENT4 promoter may be responsible for the augmented
activation of the P2 promoter by EWS/WT1(2KTS). Deletion of
the GC-rich sequences (P4) resulted in a reduced but not complete
absence of transactivation by the 2KTS, suggesting the presence
of additional cis-elements for EWS/WT1(2KTS). Interestingly,
removal of the GC-rich sequences (P4) also led to a reduction in
the EWS/WT1(+KTS)-mediated transactivation, demonstrating
that the GC-rich sequences are needed to achieve full transactiva-
tion by EWS/WT1(+KTS).
To precisely define the 2KTS-specific response elements in the
GC-rich region of the ENT4 promoter, we introduced base
substitutions within the three potential EWS/WT1(2KTS)
binding sites of the P2 promoter (Fig. 2D). Mutation of the first
potential binding site M1 at +370 (59-GAGGGGGTC-39 to
GAAAAAATC-39) had no effect on the EWS/WT1(2KTS)-
mediated activation of the promoter (Fig. 2E). However, mutation
of the second binding site M2 at +440 (antisense strand: 59-
GCGGGGGGG-39 to 59-GCGGAAAAA-39) resulted in approx-
imately 60% reduction in the activation of the P2 promoter by the
2KTS isoform. Altering the third site M3 at +570 (59-
CTGGGGGCG-39 to 59-CTAAAAACG-39) showed a slight
decrease in the EWS/WT1(2KTS)-mediated transactivation,
but it was not statistically significant. Consistent with this,
mutations at both the M2 and M3 sites (the M2/M3 promoter)
in the GC-rich region displayed a similar level of reduction in the
reporter assay as the single M2 mutation (Fig. 2E), demonstrating
that the M2, but not the M1 or the M3 sites, functions as the cis-
regulatory element for EWS/WT1(2KTS). These observations
also indicate the existence of other EWS/WT1(2KTS) responsive
element(s) within the GC-rich region. EWS/WT1(+KTS) had no
discernible activity on any of the base substituted promoters
(Fig. 2E). We did not attempt to define the +KTS responsive
element in the GA-repeat sequences due to the presence of more
than 50 potential E(KTS)RE sites.
EWS/WT1 is recruited to ENT4 promoter in vivo
We next performed chromatin immunoprecipitation (ChIP)
assay to determine whether EWS/WT1 is recruited to the ENT4
Figure 1. Identification of ENT4 as a target of EWS/WT1 in DSRCT. A. Schematic representation of EWS/WT1 chimeric protein. The activation
domain of EWS and the three zinc fingers of WT1 (DNA biding domain) are indicated. KTS indicates the alternative KTS splicing. B. Induction of ENT4
expression by both isoforms of EWS/WT1. Total RNA isolated from cells with Tet-repressible expression of EWS/WT1(2KTS) (UF-5), EWS/WT1(+KTS)
(UED5) and empty vector (UV9) grown in the presence or absence of Tet for 12 hrs was analyzed by qRT-PCR using ENT4 TaqMan probe (Applied
Biosystems). Fold induction represents the level of ENT4 expression following the inducible expression of EWS/WT1 (2Tet) relative to the uninduced
(+Tet). Data were analyzed by comparative Ct method using GAPDH as a control. C. Expression of ENT4 in primary DSRCT and Ewing’s sarcoma
specimens, and in normal human tissues. Total RNAs isolated from primary tumors of DSRCT and Ewing’s sarcoma specimens and from normal
human brain, heart and spleen were analyzed for ENT4 and GAPDH expression using TaqMan quantitative RT-PCR. Relative expression of ENT4 is
shown as the ratio of ENT4 transcripts relative to GAPDH transcripts (note the scale difference in the left and the right panels). D. RNA in situ
hybridization of ENT4 in DSRCT. Two frozen DSRCT samples were sectioned and hybridized to ENT4 riboprobes. ENT4 expression is restricted to tumor
cells (antisense probe). No staining was observed with a control (sense) probe. Tumor sections were also stained with hemotoxylin and eosin (H&E).
doi:10.1371/journal.pone.0002353.g001
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EWS/WT1(2KTS) and EWS/WT1(+KTS), respectively, and
formaldehyde-crosslinked DNA was immunoprecipitated using an
antibody that recognizes the C-terminal domain of WT1 (C-19) to
enrich for the chromatin bound by EWS/WT1. The endogenous
WT1 is not detectable in U2OS cells by western blotting (data not
shown), and thus, the C-19 antibody should be specific for EWS/
WT1. We designed primers flanking the GC-rich sequences to
examine the EWS/WT1(2KTS) binding and a primer set near
the 59 region of the GA-repeat sequences for detecting the EWS/
WT1(+KTS) recruitment (Fig. 3B). ChIP analysis of UF5 cells
demonstrated that EWS/WT1(2KTS) was present near the GC-
rich region of ENT4 promoter as shown by the specific
amplification of the GC-rich sequences with the chromatin
immunoprecipitated with C-19 antibodies but not with the IgG-
immunoprecipitated chromatin control (Fig. 3B, UF5 panel).
Similarly, ChIP analysis of UED5 cells showed in vivo recruitment
of EWS/WT1(+KTS) to the GA-repeat region of the ENT4
promoter (Fig. 3B, UED5 panel). Recruitment of the EWS/WT1
isoforms to these regions of the ENT4 promoter was specific since
the control primers amplifying the regions either 1kb upstream
from the GA-repeat region (CONT1) or 1kb downstream from the
GC-rich region (CONT2) failed to amplify any product.
A DSRCT cell line, JN-DSRCT-1, is the only established cell
line derived from a primary DSRCT specimen and naturally
expresses both isoforms of EWS/WT1 [30]. The breakpoint of
EWS/WT1 translocation in JN-DSRCT-1 cell line is different
(intron 10 of EWS) from the prototypical EWS/WT1 translocation
(intron 7 of EWS) expressed in UF5 and UED5 cells. Thus, JN-
DSRCT-1 cells express slightly slower migrating isoforms of
EWS/WT1 (Fig. 3A). Immunoblot analysis with the C-19
antibody further revealed that JN-DSRCT-1 cells do not express
detectable levels of endogenous WT1. To determine whether
naturally occurring EWS/WT1 is recruited to the ENT4
promoter, we performed the ChIP analysis in JN-DSRCT-1 cells.
Consistent with our previous ChIP results, EWS/WT1 was
physically recruited near the two cis-elements in the ENT4
promoter in JN-DSRCT-1 cells as demonstrated by specific
PCR amplifications of both the GA-repeat and the GC-rich
regions of the promoter with chromatin immunoprecipitated with
antibodies to WT1 (C-19), but not with IgG (Fig. 3C). As expected,
the control primers (CONT1, CONT2 and GAPDH) did not yield
any PCR products. Since the antibody (C-19) recognizes both
isoforms of EWS/WT1, we cannot demonstrate the recruitment of
each isoform to the specific regions of the ENT4 promoter in JN-
DSRCT-1 cells. However, based on our previous results (Fig. 2C
and 3B), it is likely that each isoform is recruited to the respective
cis-regulatory elements of the ENT4 promoter in JN-DSRCT-1
cells. Interestingly, we consistently observed a more robust
amplification of the GA-repeat region than the GC-rich region
in our ChIP assays (Fig. 3B and C), which may indicate the
presence of more EWS/WT1 in the GA-repeat region (which
Figure 2. Identification of EWS-WT1(+KTS) and (2KTS) responsive elements in the human ENT4 promoter. A. Schematic representation
of ENT4 gene. The dark grey box indicated by +1 represents the first non-coding exon and the transcription start site (+1). The second dark grey box
marked by ATG represents exon 2 containing the starting ATG. The light grey box represents the GA-repeat sequence. The black box represents the
GC-rich sequence. B. Schematics showing the luciferase reporter constructs (P1–P4) containing different fragments of the ENT4 promoter. P3
promoter construct contains the deletion of GA-repeat sequences (2915 to +272). The numbers are relative to the transcription start (+1). C. Direct
transcriptional activation of ENT4 promoters by EWS/WT1. U2OS cells were co-transfected with either pcDNA3-EWS/WT1 (2 or +KTS; 0.5 mg) or with
pcDNA3 along with the promoter-reporter constructs (P1, P2, P3 or P4; 0.5 mg) and Renilla luciferase (0.1 mg) using FuGENE 6. Luciferase activity was
measured at 48 hrs post-transfection and expressed as relative luciferase activity compared to the empty vector. Data represent the mean6S.D. from
three independent experiments. D. Schematics showing the three putative EWS/WT1(2KTS) binding sites (black boxes) within the GC-rich region of
the P2 promoter and the mutated derivatives, M1, M2, M3 and M2/M3 constructs (see Materials and Methods for detail). E. Identification of the EWS/
WT1(2KTS) responsive element M2. Luciferase-reporter assay was performed as in (C) except with the promoter-reporter constructs shown in (D).
Data represent the mean6S.D. from three independent experiments.
doi:10.1371/journal.pone.0002353.g002
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PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2353Figure 3. Direct in vivo recruitment of EWS/WT1(6KTS) to ENT4 promoter. A. Western blot analysis of EWS/WT1 in the inducible cell lines
(UF5 and UED5) and in the primary DSRCT cell line (JN-DSRCT-1), probed with anti-EWS antibody (upper panel) or with anti-WT1 antibody (lower
panel, C-19, Santa Cruz). EWS/WT1 expression was induced (2Tet) for about 14 hrs in UF5 and UED5 cells. B. Chromatin immunoprecipitation (ChIP)
analysis. Schematics of ENT4 promoter and the locations of the primers (arrows) used to amplify the GA-repeat and the GC-rich regions are shown.
EWS/WT1(+KTS) or (2KTS) expression was induced for 14 hrs in UED5 and UF5 cells, respectively, and crosslinked with 1% formaldehyde. Crosslinked
chromatin immunoprecipitated with anti-WT1 antibody (C-19, Santa Cruz) or rabbit IgG control was used in PCR amplification with either primers in
the GA-repeat (for UED5 cells) or the GC-rich (for UF5 cells) regions of the human ENT4 promoter. Primers amplifying the control regions of the ENT4
promoter (CONT1 and CONT2) and GAPDH promoter were used as negative controls. C. ChIP analysis in JN-DSRCT-1 cells. Formaldehyde-crosslinked
chromatin from JN-DSRCT-1 cells was examined by ChIP analysis using the same primer sets as in (B).
doi:10.1371/journal.pone.0002353.g003
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er, these results demonstrate that EWS/WT1 is recruited to the
proximal promoter region of ENT4 in vivo.
ENT4 is highly and specifically expressed in JN-DSRCT cell
line
We next sought to determine the expression level of ENT4 in
JN-DSRCT-1 cells. For comparison, we used two Ewing’s
sarcoma cell lines A4573 and CHP100, both of which express
the EWS/FLI-1 translocation gene product. A quantitative
measurement of the transcripts by qRT-PCR revealed that
expression of ENT4 was about 15- to 30-fold higher in JN-
DSRCT-1 cells when compared to A4573 and CHP100 cells,
respectively (Fig. 4A). Expression of other equilibrative nucleoside
transporters (ENT1-3) was not enriched in JN-DSRCT-1 cells.
Expression of ENT4 was also at least 50-fold or higher in JN-
DSRCT-1 cells than in three other human cancer cell lines
examined, PC3, DU-145 and U2OS (Supplement Fig. S2). These
results clearly demonstrate that ENT4 is highly and specifically
enriched in JN-DSRCT-1 cells, consistent with the highly
abundant expression of ENT4 in the primary DSRCT (Fig. 1C
and D).
To further demonstrate that EWS/WT1 is directly regulating
the ENT4 expression, we used a small interfering RNA (siRNA)
approach to deplete the level of EWS/WT1 in JN-DSRCT-1 cells.
As shown in Fig. 4B, transfection of two different siRNAs directed
against the 39 UTR of WT1 resulted in a marked reduction in the
level of EWS/WT1 as compared to the control siRNA. Depletion
of EWS/WT1 by two independent WT1-siRNAs concomitantly
led to approximately 60% decrease in the ENT4 transcripts
(Fig. 4C), further supporting the direct transcriptional regulation of
ENT4 by EWS/WT1.
Adenosine analog 2-CdA displays increased cytotoxicity
in JN-DSRCT cells
Nucleoside transporters are thought to be important for the
efficacy of nucleoside analogs used in chemotherapy such as
gemcitabine, a pyrimidine nucleoside analog [31,32]. Despite the
initial classification of ENT4 as an adenosine transporter and a
new member of equilibrative nucleoside transporter [29], ENT4
was shown to be a poor transporter of adenosine at neutral pH
[28]. Recently, however, it was demonstrated that ENT4 exhibits
a maximum adenosine transporter activity at pH 6.0 to 6.6 and is
primarily localized at the plasma membrane [26,27]. To examine
whether we can exploit the high level of ENT4 expression and its
adenosine transporter activity in DSRCT, we treated JN-DSRCT-
1 and the control cells, A4573 and CHP100, with various
nucleoside analogs: 2-chloro-29-deoxyadenosine (2-CdA, also
known as cladribine), 2-fluoroadenine-9-b-D-arabinofuranoside
(F-ara-A, also known as fludarabine), or 5-fluorouracil (5-FU) as a
pyrimidine analog control. For comparison, we also treated cells
with doxorubicin, a highly cytotoxic chemotherapeutic compound
used to treat DSRCT patients [33]. When cells were cultured at
pH 6.6 and treated with a low dose (0.1 mM) of 2-CdA, JN-
DSRCT-1 cells displayed a modest but significant increase in
sensitivity to 2-CdA while the control A4573 and CHP100 cells
remained fully viable under the same condition (Fig. 5A). Under
the standard culture condition (pH 7.4), the same dose of 2-CdA
(0.1 mM) had no cytotoxic effects on JN-DSRCT-1 cells (Fig. 5A).
A higher dose of 2-CdA (1 mM) at pH 6.6 also led to a significant
increase in cytotoxicity in JN-DSRCT-1 cells as compared to the
control cells. At the highest dosage (10 mM), 2-CdA was highly
cytotoxic to all cells examined. In contrast, different doses up to
1 mM of F-ara-A under pH 6.6 were not cytotoxic to any of the
cell lines tested. However, 10 mM of F-ara-A at pH 6.6 resulted in
a dramatic increase in cytotoxicity in JN-DSRCT-1 cells
compared to the control cells (Fig. 5A). The same dose of F-ara-
A (10 mM) at neutral pH 7.4 had only a marginal effect on JN-
DSRCT-1 cell viability (see pH 7.4 panel). Increasing doses of 5-
FU showed minimal cytotoxicity in all cells cultured at either pH
conditions. Doxorubicin treatment at pH 6.6 resulted in a similar
dose-dependent cytotoxicity as that observed under the neutral
pH.
To examine whether reducing the ENT4 transcript level by
WT1-siRNA could decrease the cytotoxicity of 2-CdA and F-ara-
A, JN-DSRCT-1 cells were transfected with control or WT1-
siRNAs, followed by treatment with 1 mM of 2-CdA or 10 mMo f
F-ara-A at pH 6.6. Decreasing the level of ENT4 with WT1-2
siRNA resulted in a markedly reduced cytotoxicity to 2-CdA
treatment (Fig. 5B). WT1-1 siRNA transfected cells also showed
slightly reduced cytotoxicity to 2-CdA, but it did not reach
statistical significance. By contrast, transfection of either WT1
siRNAs resulted in a significant reduction in F-ara-A (10 mM)
mediated cytotoxicity at pH 6.6 (Fig. 5C). Collectively, these
results are consistent with the cytotoxic effects of 2-CdA and F-ara-
A being mediated, at least in part, through ENT4 in JN-DSRCT-1
cells.
Discussion
DSRCT-specific EWS/WT1 translocation results in the
production of two fusion proteins with distinct biological activities,
which has not been observed in other EWS-related chromosomal
translocations. Two EWS/WT1 isoforms possess different DNA
binding specificity due to the alternative KTS splicing event [18].
In addition, EWS/WT1(+KTS) could potentially have a non-
transcriptional role since WT1(+KTS) isoform has recently been
demonstrated to bind to cellular mRNA [34] and participate in
the control of translation [35]. Thus, the existence of two isoforms
of EWS/WT1 in DSRCT raises the following interesting
questions: what are the roles of each isoforms and are they both
required for tumorigenesis? The latter question has been
addressed by Kim et al [19] who demonstrated that, at least in
vitro, only the EWS/WT1(2KTS) isoform possesses the trans-
forming activity using the NIH3T3 cell-based transformation
assays. However, it remains to be determined whether the 2KTS
isoform is sufficient for tumorigenesis in vivo.
To address the oncogenic role of EWS/WT1, most of the efforts
have been focused on identifying the transcriptional target of the
2KTS isoform due to its in vitro transforming property. Because of
altered DNA binding properties of the 2KTS and the +KTS
isoforms, it is presumed that their target genes would be different.
Consistent with this notion, nearly all of the EWS/WT1 target
genes identified are transcriptionally regulated only by the EWS/
WT1(2KTS) isoform [20–24]. In contrast, LRRC15 is the only
EWS/WT1(+KTS) target gene identified to date and is solely
regulated by the +KTS [25]. Therefore, it was quite surprising to
find that ENT4 was transcriptionally activated by both isoforms of
EWS/WT1.
The promoter analysis revealed that the transcriptional
activation by two EWS/WT1 isoforms is mediated through
different cis-regulatory elements within the ENT4 promoter. The
GA-repeat sequences, which contain more than 50 potential
binding sites for EWS/WT1(+KTS), mediate transactivation by
the +KTS, whereas the GC-rich sequences containing the
responsive element, M2, functioned as the cis-regulatory elements
for the 2KTS-specific transactivation (Fig. 2). The existence of
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an intriguing possibility of synergistic transcriptional activation by
the two isoforms on the ENT4 promoter. However, coexpression
of both isoforms did not result in a synergistic activation of the
ENT4 promoter (data not shown). Our findings further suggest
that EWS/WT1(+KTS) may play a more prominent role in the
activation of ENT4 transcription than EWS/WT1(2KTS), based
on the higher induction level of endogenous ENT4 transcripts by
the +KTS isoform (Fig. 1B), higher transactivation by the +KTS in
our promoter-reporter analysis (Fig. 2C), and by our ChIP analysis
in which we observed a more robust amplification of the GA-
repeat region than the GC-rich region of ENT4 promoter (Fig. 3C).
A likely explanation for this is the presence of more than fifty
EWS/WT1(+KTS) binding sites in the GA-repeat region. This
may also help to explain the remarkably high level of ENT4
expression observed in both primary DSRCT specimens and JN-
DSRCT-1 cell line, as well as the lack of synergy between the two
isoforms in our promoter assay (the +KTS isoform may simply
saturate the promoter). A highly abundant expression of ENT4
may be useful as an additional diagnostic marker of DSRCT
although more cases need to be evaluated. Our study further
suggests that it may be possible to identify additional target genes
of EWS/WT1(+KTS) by examining the proximal promoter
regions for the GA-repeat sequences.
ENT4 is a member of the equilibrative nucleoside transporter
(ENT) family (SLC29), which contains four isoforms [29]. ENT1
and ENT2 transport purine and pyrimidine nucleosides (e.g.
uridine, adenosine, etc.) and their structural analogs. ENT3 is an
intracellular nucleoside transporter, which may play a role in
lysosomal transport of nucleosides [36]. ENT4 is unique in the
ENT family as it is specific towards adenosine and adenosine
analogs and does not significantly transport other nucleosides and
Figure 4. ENT4 transcript is highly abundant in JN-DSRCT-1 cells and is regulated by EWS/WT1. A. Quantitative measurement of ENT-
family transcripts. Total RNA isolated from JN-DSRCT-1 and two Ewing’s sarcoma cells (A4537 and CHP100) was analyzed for relative transcript levels
of ENT-family genes using Taqman probes for ENT1, ENT2, ENT3, and ENT4. ENT1 transcript level from A4573 cells was arbitrarily set to 1 and used as a
reference for quantification of other ENT-family transcripts in A4573 and other cells. Data were analyzed by comparative Ct method using GAPDH as a
control. Data represent the mean6S.D. from three independent experiments. B. siRNA knockdown of EWS/WT1. JN-DSRCT-1 cells were transfected
with either control, WT1-1 or WT1-2 siRNAs using Lipofectamine
TM 2000, and at 48 hrs post-transfection, total cell lysates were analyzed by western
blotting using anti-EWS, anti-WT1 and anti-actin (loading control) antibodies. C. Total RNA was isolated from the siRNA-transfected cells (as described
in B) and the expression level of ENT4 was determined by qRT-PCR as in (A). Data represent the mean6S.D. from three independent experiments.
doi:10.1371/journal.pone.0002353.g004
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adenosine is low at pH 7.4, and recent reports have shown that
ENT4 exhibits a maximum adenosine transport activity at pH 6.0
to 6.6 [26,27]. The role of ENT4 in the genesis and progression of
DSRCT is unknown, but it may have a role in supporting
tumorigenesis by providing growth and survival advantages to the
tumor cells in adapting to a tumor microenvironment. In general,
the tumor microenvironement becomes hypoxic and acidic due to
a limiting blood supply and increased acid production from the
upregulation of glycolytic metabolic pathways by the tumor cells
Figure 5. JN-DSRCT-1 cells display dose- and pH-dependent cytotoxicity to adenosine analogs. A. Cytotoxic assay. JN-DSRCT-1, A4573,
and CHP100 cells were exposed to various concentrations (0.01–10 mM) of 2-CdA, F-ara-A, 5-FU or doxorubicin (Dox) for 72 hrs at pH 7.4 or pH 6.6.
Cell viability was determined with Cell Counting Kit-8 (Dojindo Molecular Technologies). Data represent the mean6S.D. from three independent
experiments performed in duplicate. *, p value , 0.01 was calculated by first performing one-way ANOVA analysis followed by Tukey’s multiple
comparison test. B and C. JN-DSRCT-1 cells were transfected with either control, WT1-1 or WT1-2 siRNAs using Lipofectamine
TM 2000 for 24 hrs, and
the cells were treated with either 1 mM of 2-CdA (B) or 10 mM of F-ara-A (C) at pH 6.6 for 48 hrs. The knockdown efficiency of ENT4 was confirmed by
qRT-PCR (as in Fig. 4C) and cytotoxicity was assessed by Toxilight BioAssay Kit (see Materials and Methods). Data represent the mean6S.D. from at
least three independent experiments performed in duplicate. p value was calculated by first performing one-way ANOVA analysis followed by Tukey’s
multiple comparison test.
doi:10.1371/journal.pone.0002353.g005
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angiogenesis under hypoxic conditions [38]. Thus, it is intriguing
to speculate that DSRCT-specific expression of ENT4, a pH-
dependent (acidic) adenosine transporter, might provide growth
and survival advantages to the tumor cells (e.g. by stimulating
angiogenesis) under hypoxic/acidic conditions, as well as increas-
ing the nucleoside pool within the rapidly proliferating tumor cells.
The expression level and pattern of the ENTs are an important
determinant for the therapeutic efficacy of anticancer nucleoside
analogs since many nucleoside analogs used in cancer chemo-
therapy depend on nucleoside transporters to enter tumor cells to
exert their cytotoxicity (reviewed in [39]). For example, the
expression of ENT1 in leukemia and certain solid tumors is related
to the clinical efficacy of a number of nucleoside analogs such as
cytarabine (Ara-C) and gemcitabine [39]. In light of this, our
results demonstrating the cytotoxic effects of 2-CdA and F-ara-A
in JN-DSRCT-1 cells in vitro are highly intriguing. Adenosine
analogs such as 2-CdA and F-ara-A are an effective chemother-
apeutic agent for the treatment of hairy cell leukemia and chronic
lymphocytic leukemia, respectively [40–42]. However, efficacy of
these adenosine analogs in solid tumors has not been reported.
Our finding of ENT4 as a transcriptional target of EWS/WT1
highly expressed in DSRCT suggests that this transporter may
represent an attractive pathway for targeting chemotherapeutic
drugs into DSRCT.
Materials and Methods
Cell lines
UF5, U2OS-derived cell line with tetracycline-repressible
EWS/WT1(2KTS) expression, was generated as described
previously [20]. UED5 cells with tetracycline-repressive EWS-
WT1 (+KTS) expression [25] and UV9 control cells [20] were
previously described. UV9, UF5 and UED5 were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS) and 1 mg/ml tetracycline. A human DSRCT
cell line, JN-DSRCT-1 (kindly provided by Dr. Nishio) [30] and
Ewing’s sarcoma cell lines, A4573 and CHP100 (kindly provided
by Dr. Crystal Mackall, NCI), were maintained in 1:1 mixture of
DMEM and Ham’s F-12 with 10% FBS.
Quantitative RT-PCR analysis
Total RNA was isolated from cell lines or tumor tissues with
RNA STAT-60 (Tel-Test Inc. Friendswood, TX) according to the
manufacturer’s instruction. Total RNAs from normal human
heart, brain and spleen were purchased from Zyagen (San Diego,
CA). Two microgram of total RNA was treated with 1U of DNase
I (Invitrogen, Carlsbad, CA) and reverse transcribed with
SuperScript First-Strand Synthesis System (Invitrogen). For
quantification of ENT4, equal amount of first-strand cDNA was
mixed with each assay-on–demand TaqMan probes and Taqman
Universal Master Mix (Applied Biosystems, Foster City, CA), and
amplified using ABI prism 7700 sequence detection system
(Applied Biosystems). Data were analyzed by comparative Ct
method using GAPDH as an endogenous control. For the
quantification of ENT4 in UV9, UF5 and UED5 cells, the level
of ENT4 transcripts (normalized to GAPDH) in the absence of
tetracycline was expressed as fold differences to the level of ENT4
in the presence of tetracycline (arbitrarily set to 1). For the
quantification of ENT4 in normal human tissues, primary DSRCT
and Ewing’s sarcoma specimens, the ratio of ENT4 transcripts
relative to the Glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH) transcripts was calculated using the comparative Ct
method. For the quantification of EWS/WT1 expression in UF5
and UED5 cells, the relative expression was determined by using
the Quantitect
TM SYBR Green PCR kit (Qiagen, Valencia, CA).
The primers used for this assay were: 59-TGGATCCTACAGC-
CAAGCTCC-39;5 9-TTGGTGTCTTTTGAGCTGGTCTG-39.
GAPDH was used for standardization. All experiments were done
in duplicate and data from minimum of three independent
experiments were analyzed.
ENT4 promoter constructs and luciferase reporter assays
A 2.0 kb fragment containing the human ENT4 promoter was
obtained by PCR using human genomic DNA and inserted into
the XhoI/Hind III sites of a promoterless firefly luciferase
reporter pGL3-Basic plasmid (Promega, Madison, WI) to yield
P1. The following primers were used: 59 GCGAGATCTGGTG-
GAAAGTGAAGGAAGGGCC 39;5 9 CCGTTCGAACTCAT-
CAGCCGCAAAGTTGGCTC 39. Three promoter-deletion
constructs (P2, P3 and P4) were generated by digestion of P1
with restriction enzymes and ligation of promoter fragments.
The mutant constructs (M1, M2, M3 and M2/M3) were
generated using QuickChange Multi site-Directed Mutagenesis
Kit (Stratagene, Cedar Creek, TX) using the following primers:
M1: sense, 59-GCCCTCGCCATGGAAAAAATCGGCGC-
CACCGCC-39
antisense, 59-GGCGGTGGCGCCGATTTTTTCCAT-
GGCGAGGGC-39
M2: sense, 59-CGAAGTTCCTCCCCGGATTTTTCCGC-
GCCACCCCATC-39
antisense, 59-GATGGGGTGGCGCGGAAAAATCCG-
GGGAGGAACTTCG-39
M3: sense, 59-GGGGTCTGTCCTTTGCCTAAAAACG-
CAGGTCCGCGAGC-39
antisense, 59-GCTCGCGGACCTGCGTTTTTAGGC-
AAAGGACAGACCCC-39.
The ENT4 promoter-reporter constructs (0.5 mg) were cotrans-
fected into U2OS cells using FuGENE 6 (Roche, Indianapolis,
IN), along with 0.5 mg pcDNA3-EWS/WT1(2KTS), -EWS/
WT1(+KTS), or empty vector and renilla luciferase reporter
plasmid (0.1 mg) for normalization of transfection variance.
Luciferase activity was assayed at 48 hrs post-transfection using
the Dual-Luciferase Reporter kit (Promega). Data were calculated
from minimum of three experiments performed in duplicate.
Chromatin immunoprecipitation (ChIP) analysis
ChIP analysis was performed as previously described [43] using
ChIP assay kit (Upstate, Lake Placid, NY). After induction of
EWS/WT1(2KTS) and EWS/WT1(+KTS) expression by re-
moval of tetracycline, formaldehyde was added to a final
concentration of 1% and cells were incubated at room
temperature for 10 min. Cells were lysed in SDS lysis buffer
(1% SDS, 50 mM Tris pH 8.0, 10 mM EDTA) and DNA was
sheared by sonication to achieve an average length of ,500-bp.
Samples were diluted 10-fold in ChIP Dilution Buffer and
incubated overnight at 4uC with either rabbit polyclonal anti-
WT1 (C-19, Santa Cruz, Santa Cruz, CA) or with rabbit IgG.
Samples were incubated with Salmon Sperm DNA/Protein A
Agarose-50% Slurry and bound complexes were eluted in elution
buffer (1% SDS, 0.1 M NaHCO3). Samples were incubated 4 hr
at 65uC to reverse crosslinking and proteins were digested with
Proteinase K. Following purification of DNA fragments (Qiaquick
PCR purification kit, Qiagen), ENT4 promoter regions were
amplified by PCR using primers (to detect EWS/WT1(2KTS)
binding within the GC-rich region): 59-ACCTGTCGGAG-
CCTTTGTCTG-39;5 9-ATCAGCCGCAAAGTTGGCTCG
-39, which yields a 452-bp product, and with primers (to detect
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TGCACAGCCCAGCTGGATGG-39;5 9-CCCATTCTCCTA-
CTCAGTCC-39, which yields a 218-bp product. To control for
specificity, the following primers were used: CONT1 primers: 59-
CTAGTTGGAGCAATGGACTG-39;5 9-GCTGGCATACAG-
CAGGAGCC-39 (which amplify ,1 kb upstream region of the
GA-repeats, yielding a 250-bp product); CONT2 primers: 59-
CGCAGTAGGCTTGGATGTGG-39;5 9-AATGCTCCTCCT-
GCCACCTG-39 (which amplify ,1 kb downstream sequences
of the GC-rich region, yielding a 400-bp product); and GAPDH
promoter primers: 59-TTTACGGGCGCACGTAGCTCA-39;5 9-
CACCTTCCCCATGGTGTCTGA-39, which yields a 462-bp
product.
RNA in situ analysis
RNA in situ hybridization was performed as described [23]. SP6
and T7 flanked PCR templates were used to generate digoxigenin-
labeled riboprobes (Roche Molecular Biochemicals). The follow-
ing ENT4 sequences were used as probe: human ENT4 (accession
AK092242), nt 146–583 or nt 584–941. Primary DSRCT tumor
samples were obtained from the Department of Pathology,
Memorial Sloan Kettering Cancer Center. OTC-embedded
samples were cut into 9 mm sections, fixed in 4% paraformalde-
hyde, digested with Proteinase K (4 mg/ml), treated with acetic
anhydride, and dehydrated in increasing concentrations of
ethanol. Sections were hybridized overnight with 1 ng/ml probe.
Bound probe was detected using an alkaline phosphatase
conjugated anti-digoxigenin antibody (Roche Molecular Biochem-
icals) followed by incubation with BM purple (Roche Molecular
Biochemicals), an alkaline phosphatase substrate. Control sense
riboprobes were tested for each tissue.
siRNA knockdown analysis
JN-DSRCT-1 cells were transfected with two small interfering
RNA (siRNA) against the 39 UTR of WT1 (siWT1-1 and siWT2-
2, purchased from Sigma-Aldrich, St. Louis, MO; siRNA ID:
SASI_Hs01_00130271 and SASI_Hs01_00130272, respectively)
or control scrambled siRNA. At 48 hrs post-transfection, total
RNA was isolated, reverse-transcribed and quantified by RT-PCR
using the Taqman probes against ENT4 as described above. The
knockdown of EWS/WT1 was verified by western blotting using
rabbit polyclonal anti-EWS (1:1000 dilution, [11]), anti-WT1 (C-
19) (1:200 dilution, Santa Cruz Biotechnology) and anti-Actin
(1:1000 dilution, Sigma-Aldrich) antibodies. All blots were
visualized by Odyssey infrared system (LI-COR Bioscience,
Lincoln, Nebraska).
In vitro cytotoxicity assays
Ewing’s sarcoma cell lines, A4573 and CHP100, and the
DSRCT cell line, JN-DSRCT-1, were seeded (5610
4 cells/well) in
24-well plates and allowed to adhere for 24 hrs prior to treatments
with increasing doses (0.01 to 10 mM) of doxorubicin or various
nucleoside analogs, 2-Chloro-29-deoxyadenosine (2-CdA, also
known as cladribine), 2-Fluoroadenine-9-b-D-arabinofuranoside
(F-ara-A, also known as fludarabine), and 5-fluorouracil (5-FU). All
chemicals were purchased from Sigma-Aldrich. For an acidic
culture condition, DMEM-F12 medium (pH 7.4) was adjusted to
pH 6.6 by the addition of non-essential amino acids (1006,
Invitrogen). The cytotoxicity of various drugs were measured using
the Cell Counting Kit–8 (Dojindo Molecular Technologies, Inc.
Gaithersburg, MD), a variant of an MTT assay which measures
the conversion of a substrate to a water soluble formazan salt by
sepctrophotometric quantification at 450 nm [44]. Dose-response
curve and standard deviation were determined from three
independent experiments performed in duplicate. For siRNA
knockdown experiments, 3610
5 of JN-DSRCT-1 cells were
seeded in 12-well plate and transfected with 100 pmol of each
siRNA using Lipofectamine
TM 2000 (Invitrogen). Twenty-four
hours post-transfection, cells were treated with either 1 mMo f2 -
CdA or 10 mM of F-ara-A at pH 6.6 for another 48 hrs. The
knockdown efficiency of EWS/WT1 was confirmed by western
blotting. The cytotoxicity was assessed by an independent method
using ToxiLight BioAssay Kit (Lonza, Rockland, ME), which
quantitatively measures the release of adenylate kinase (AK)
from damaged cells [45]. The percent AK release was calcu-
lated using the following formula: (RLUTreated2RLUUntreated)/
RLUUntreated6100, where RLU represents the relative lumines-
cence unit. All p values were calculated using one-way ANOVA
analysis followed by Tukey’s multiple comparison test.
Supporting Information
Figure S1 Quantitative RT-PCR analysis of EWS/WT1(+KTS)
and EWS/WT1(2KTS) expression in UED5 and UF5 cells.
Quantitative RT-PCR analysis of EWS/WT1(2KTS) and EWS/
WT1(+KTS) expression in UF5 and UED5 cells. Total RNA was
isolated from UF5 and UED5 cells grown in the presence or
absence of tetracycline (Tet) for 14 hrs and expression of EWS/
WT1 in the absence of Tet was quantified by SYBR Green PCR
and expressed as relative to the level in the uninduced (+Tet).
GAPDH was amplified as a reference normalization control.
Found at: doi:10.1371/journal.pone.0002353.s001 (0.39 MB TIF)
Figure S2 Expression of ENT4 in human cancer cell lines.
Quantative RT-PCR analysis of ENT4 in human cancer cell lines.
Total RNA was isolated from two human prostate cancer cell
lines, DU-145 and PC3, an osteosarcoma cell line U2OS, and the
JN-DSRCT-1 cell line, and the expression level of ENT4 was
quantified by quantitative RT-PCR using assay-on-demand
TaqMan ENT4 and GAPDH probes (Applied Biosystems, Foster
City, CA). Data were analyzed by comparative Ct method using
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) as an
endogenous control. The expression level of ENT4 in DU-145
cells was arbitrarily set to a reference value of 1 and used to
compare the level of ENT4 expression in other cell lines.
Found at: doi:10.1371/journal.pone.0002353.s002 (0.42 MB TIF)
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